AstraZeneca has agreed to acquire the Belgian biotech company EsoBiotec for $1 billion, focusing on cancer immunotherapies. EsoBiotec's innovative approach allows for in-vivo cell therapies that can rapidly empower the immune system to fight cancer, enabling treatments to be delivered quickly through injections instead of the traditional lengthy process. This acquisition reflects AstraZeneca's strategy to expand its global operations and enhance patient access to advanced treatments. The executive vice-president highlighted its transformative potential in the field of cell therapy, emphasizing the urgency and accessibility of treatment methodologies for various cancers, including multiple myeloma.
Susan Galbraith, the executive vice-president of oncology research and development at AstraZeneca, said: "We believe it has the potential to transform cell therapy and will enable us to scale these innovative treatments so that many more patients around the world can access them."
AstraZeneca has struck a $1bn deal to buy a Belgian biotech company EsoBiotec, which specializes in cancer immunotherapies and aims to provide quicker cell therapy treatments.
EsoBiotec's treatment uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, like T-cells, allowing rapid administration through simple injections.
This deal represents AstraZeneca's persistence in expanding its global operations, allowing for urgent access to potentially revolutionary treatments in the field of immunotherapy.
Collection
[
|
...
]